PL3215530T3 - Ulepszone przeciwciała anty-il-6 - Google Patents
Ulepszone przeciwciała anty-il-6Info
- Publication number
- PL3215530T3 PL3215530T3 PL15797538T PL15797538T PL3215530T3 PL 3215530 T3 PL3215530 T3 PL 3215530T3 PL 15797538 T PL15797538 T PL 15797538T PL 15797538 T PL15797538 T PL 15797538T PL 3215530 T3 PL3215530 T3 PL 3215530T3
- Authority
- PL
- Poland
- Prior art keywords
- antibodies
- improved anti
- improved
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462077105P | 2014-11-07 | 2014-11-07 | |
| US201462087448P | 2014-12-04 | 2014-12-04 | |
| US201562247705P | 2015-10-28 | 2015-10-28 | |
| EP15797538.4A EP3215530B9 (en) | 2014-11-07 | 2015-11-06 | Improved il-6 antibodies |
| PCT/US2015/059532 WO2016073890A1 (en) | 2014-11-07 | 2015-11-06 | Improved il-6 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3215530T3 true PL3215530T3 (pl) | 2020-05-18 |
Family
ID=54602042
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15797538T PL3215530T3 (pl) | 2014-11-07 | 2015-11-06 | Ulepszone przeciwciała anty-il-6 |
| PL23189385.0T PL4268843T3 (pl) | 2014-11-07 | 2015-11-06 | Ulepszone przeciwciała IL-6 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL23189385.0T PL4268843T3 (pl) | 2014-11-07 | 2015-11-06 | Ulepszone przeciwciała IL-6 |
Country Status (33)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10072075B2 (en) | 2015-09-23 | 2018-09-11 | Genentech, Inc. | Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis |
| US20190046642A1 (en) * | 2016-02-23 | 2019-02-14 | Eleven Biotherapeutics, Inc. | Il-6 antagonist formulations and uses thereof |
| CN110291108A (zh) * | 2016-12-19 | 2019-09-27 | 格兰马克药品股份有限公司 | 新型tnfr激动剂及其用途 |
| PE20191758A1 (es) | 2017-03-22 | 2019-12-12 | Genentech Inc | Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares |
| AR111190A1 (es) | 2017-03-22 | 2019-06-12 | Genentech Inc | Composiciones en hidrogel de prodrogas entrecruzadas de ácido hialurónico y métodos relacionados |
| CN109867723B (zh) * | 2017-12-05 | 2022-06-17 | 南京金斯瑞生物科技有限公司 | 抗人il6单克隆抗体及其制备方法和用途 |
| TW202144410A (zh) | 2020-03-13 | 2021-12-01 | 美商建南德克公司 | 抗介白素－３３抗體及其用途 |
| CR20220489A (es) | 2020-03-24 | 2022-10-31 | Genentech Inc | Agentes de fijación a tie2 y métodos de uso. |
| WO2022079161A1 (en) | 2020-10-15 | 2022-04-21 | F. Hoffmann-La Roche Ag | Non-covalent protein-hyaluronan conjugates for long-acting ocular delivery |
| CN116355825A (zh) * | 2022-02-25 | 2023-06-30 | 南京工业大学 | 一种强化纤维素合成来提高人表皮生长因子分泌生产效率的方法 |
| CN115343483B (zh) * | 2022-08-12 | 2024-11-26 | 苏州邦器生物技术有限公司 | 一种自身免疫性糖尿病检测用试剂盒及其制备方法 |
| CA3264497A1 (en) * | 2022-10-24 | 2024-05-02 | F. Hoffmann-La Roche Ag | Predicting response to il-6 antagonists |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4548990A (en) | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| JPH06508511A (ja) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的な結合ペアーの構成員の製造方法 |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| EP1279731B1 (en) | 1991-03-01 | 2007-05-30 | Dyax Corporation | Process for the development of binding mini-proteins |
| ES2315612T3 (es) | 1991-04-10 | 2009-04-01 | The Scripps Research Institute | Genotecas de receptores heterodimericos usando fagemidos. |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| CA2119930C (en) | 1991-09-23 | 2002-10-01 | Hendricus R. J. M. Hoogenboom | Production of chimeric antibodies - a combinatorial approach |
| ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
| EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| DE69329974T2 (de) | 1992-12-04 | 2001-07-19 | Medical Research Council, London | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| FR2734739B1 (fr) | 1995-06-01 | 1997-07-11 | Gec Alsthom Stein Ind | Dispositif de surveillance d'un broyeur a boulets |
| TW311927B (enExample) | 1995-07-11 | 1997-08-01 | Minnesota Mining & Mfg | |
| EP0795743A3 (en) | 1996-03-15 | 1998-02-25 | Japan Tobacco Inc. | Method and apparatus for infra-red moisture measurement |
| US5839430A (en) | 1996-04-26 | 1998-11-24 | Cama; Joseph | Combination inhaler and peak flow rate meter |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| US6358058B1 (en) | 1998-01-30 | 2002-03-19 | 1263152 Ontario Inc. | Aerosol dispensing inhaler training device |
| DE69941267D1 (de) | 1998-12-10 | 2009-09-24 | Bristol Myers Squibb Co | Proteingerüste für antikörper-nachahmer und andere bindende proteine |
| CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| AU2002256371B2 (en) | 2001-04-26 | 2008-01-10 | Amgen Mountain View Inc. | Combinatorial libraries of monomer domains |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| IL161677A0 (en) | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| WO2003094888A1 (en) | 2002-05-07 | 2003-11-20 | Control Delivery Systems, Inc. | Processes for forming a drug delivery device |
| JP2006516957A (ja) * | 2002-11-15 | 2006-07-13 | セントカー・インコーポレーテツド | Ｉｌ−６アンタゴニストの抗血管形成用途 |
| CA2551097A1 (en) | 2003-12-23 | 2005-07-14 | Rinat Neuroscience Corp. | Agonist anti-trkc antibodies and methods using same |
| ES2426816T3 (es) | 2004-08-04 | 2013-10-25 | Mentrik Biotech, Llc | Regiones Fc variantes |
| US20060204493A1 (en) | 2004-09-02 | 2006-09-14 | Genentech, Inc. | Heteromultimeric molecules |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1966244B1 (en) | 2005-12-30 | 2012-03-21 | Merck Patent GmbH | Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130 |
| CA2644405A1 (en) | 2006-03-13 | 2007-09-20 | Ablynx N.V. | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| DK2021463T3 (en) | 2006-05-19 | 2017-01-16 | Alder Biopharmaceuticals Inc | Culture method to obtain a cloned population of antigen-specific B cells |
| MX2009012492A (es) | 2007-05-21 | 2010-01-20 | Alder Biopharmaceuticals Inc | Anticuerpos para il-6 y sus usos. |
| AU2008299885C1 (en) | 2007-09-14 | 2015-06-25 | Sanofi Pasteur Biologics, Llc | Pharmaceutical compositions containing clostridium difficile toxoids A and B |
| EA201000844A1 (ru) | 2007-11-21 | 2011-10-31 | Амген Инк. | Связывающие wise агенты и эпитопы |
| US20100187601A1 (en) | 2007-12-12 | 2010-07-29 | Fujio Masuoka | Semiconductor device |
| CA2711984A1 (en) | 2008-01-15 | 2009-07-23 | Abbott Gmbh & Co. Kg | Powdered protein compositions and methods of making same |
| JP5815403B2 (ja) | 2008-08-05 | 2015-11-17 | ノバルティス アーゲー | 補体タンパク質ｃ５を標的とする抗体に関する組成物および方法 |
| DK2324930T3 (da) | 2008-09-12 | 2012-12-10 | Kdf Co Ltd | Vandsprøjteindretning |
| WO2010039750A2 (en) | 2008-10-01 | 2010-04-08 | Monsanto Technology Llc | Transgenic plants with enhanced agronomic traits |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| CA2744055A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Polypeptides, antibody variable domains & antagonists |
| SG10201704214VA (en) | 2009-01-29 | 2017-06-29 | Medimmune Llc | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| EP2593142B8 (en) | 2010-07-12 | 2018-12-26 | Pfizer Healthcare Ireland | Multifunctional antibody conjugates |
| RS62509B1 (sr) | 2012-07-13 | 2021-11-30 | Roche Glycart Ag | Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti |
| BR112015008186A2 (pt) | 2012-10-25 | 2017-09-19 | Medimmune Llc | formulação de um anticorpo estável e de baixa viscosidade |
| HK1211599A1 (en) | 2012-11-08 | 2016-05-27 | Eleven Biotherapeutics, Inc. | Il-6 antagonists and uses thereof |
| SG10201708882TA (en) | 2013-07-12 | 2017-12-28 | Ophthotech Corp | Methods for treating or preventing ophthalmological conditions |
| WO2016073894A1 (en) | 2014-11-07 | 2016-05-12 | Eleven Biotherapeutics, Inc. | Therapeutic agents with increased ocular retention |
-
2015
- 2015-11-06 PH PH1/2017/500809A patent/PH12017500809B1/en unknown
- 2015-11-06 MY MYPI2017000609A patent/MY185114A/en unknown
- 2015-11-06 FI FIEP23189385.0T patent/FI4268843T3/fi active
- 2015-11-06 HU HUE15797538A patent/HUE046181T2/hu unknown
- 2015-11-06 PE PE2017000804A patent/PE20171107A1/es unknown
- 2015-11-06 SG SG11201703574VA patent/SG11201703574VA/en unknown
- 2015-11-06 JP JP2017543332A patent/JP6594438B2/ja active Active
- 2015-11-06 RS RS20251073A patent/RS67353B1/sr unknown
- 2015-11-06 ES ES15797538T patent/ES2756275T3/es active Active
- 2015-11-06 DK DK15797538T patent/DK3215530T3/da active
- 2015-11-06 HR HRP20191945TT patent/HRP20191945T1/hr unknown
- 2015-11-06 ES ES23189385T patent/ES3051832T3/es active Active
- 2015-11-06 SI SI201530995T patent/SI3215530T1/sl unknown
- 2015-11-06 WO PCT/US2015/059532 patent/WO2016073890A1/en not_active Ceased
- 2015-11-06 UA UAA201705592A patent/UA122673C2/uk unknown
- 2015-11-06 CN CN201580065652.6A patent/CN107249631B/zh active Active
- 2015-11-06 LT LTEP23189385.0T patent/LT4268843T/lt unknown
- 2015-11-06 PL PL15797538T patent/PL3215530T3/pl unknown
- 2015-11-06 EP EP15797538.4A patent/EP3215530B9/en active Active
- 2015-11-06 US US15/524,727 patent/US11142571B2/en active Active
- 2015-11-06 SG SG10202103420PA patent/SG10202103420PA/en unknown
- 2015-11-06 AU AU2015342882A patent/AU2015342882B2/en active Active
- 2015-11-06 KR KR1020247004699A patent/KR102770849B1/ko active Active
- 2015-11-06 IL IL251858A patent/IL251858B/en unknown
- 2015-11-06 SM SM20250415T patent/SMT202500415T1/it unknown
- 2015-11-06 PT PT157975384T patent/PT3215530T/pt unknown
- 2015-11-06 KR KR1020177014412A patent/KR102636726B1/ko active Active
- 2015-11-06 DK DK23189385.0T patent/DK4268843T3/da active
- 2015-11-06 RS RS20191447A patent/RS59805B1/sr unknown
- 2015-11-06 EP EP23189385.0A patent/EP4268843B1/en active Active
- 2015-11-06 CR CR20170231A patent/CR20170231A/es unknown
- 2015-11-06 EP EP19189890.7A patent/EP3632931A1/en active Pending
- 2015-11-06 MA MA62787A patent/MA62787B1/fr unknown
- 2015-11-06 EA EA201791005A patent/EA035199B1/ru not_active IP Right Cessation
- 2015-11-06 MA MA051554A patent/MA51554A/fr unknown
- 2015-11-06 MX MX2017005992A patent/MX385206B/es unknown
- 2015-11-06 PT PT231893850T patent/PT4268843T/pt unknown
- 2015-11-06 PL PL23189385.0T patent/PL4268843T3/pl unknown
- 2015-11-06 CA CA2965689A patent/CA2965689C/en active Active
- 2015-11-06 HR HRP20251312TT patent/HRP20251312T1/hr unknown
-
2017
- 2017-04-28 ZA ZA201702985A patent/ZA201702985B/en unknown
- 2017-05-03 SA SA517381458A patent/SA517381458B1/ar unknown
- 2017-05-05 CL CL2017001135A patent/CL2017001135A1/es unknown
- 2017-05-08 MX MX2021008663A patent/MX2021008663A/es unknown
- 2017-05-30 CO CONC2017/0005404A patent/CO2017005404A2/es unknown
-
2021
- 2021-09-13 US US17/473,696 patent/US20220169719A1/en not_active Abandoned
-
2024
- 2024-05-13 US US18/662,445 patent/US20250059270A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251963A0 (en) | Anti-pd-1 antibodies | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| DK3350218T3 (da) | Polyomavirus-neutraliserende antistoffer | |
| PL3556777T3 (pl) | Konstrukty przeciwciał wieloswoistych | |
| PT3101032T (pt) | Onjugado de anticorpo anti-her2-fármaco | |
| DK3126395T3 (da) | Multispecifikke antistoffer | |
| HUE060878T2 (hu) | Anti-transztiretin antitestek | |
| EP3182987C0 (en) | HUMANIZED ANTI-TAU ANTIBODIES | |
| DK3160994T3 (da) | Multispecifikke antigenbindende proteiner | |
| DK3183272T3 (da) | Asymmetriske multispecifikke antistoffer | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| IL256099A (en) | Antibody | |
| DK3157559T3 (da) | Anti-axl-antistoffer | |
| IL291164A (en) | Anti-nme antibody | |
| PL3215530T3 (pl) | Ulepszone przeciwciała anty-il-6 | |
| LT3092003T (lt) | Naujas anti-netrino-1 antikūnas | |
| IL257368A (en) | Antibody | |
| DK3484921T3 (da) | Anti-IL-22R antistoffer | |
| DK3452515T3 (da) | Her-2-bindende antistoffer | |
| HRP20182029T1 (hr) | Uti-fuzijski proteini | |
| LT3178931T (lt) | Anti-orai1 antikūnas | |
| LT3126391T (lt) | Hpa-1a antikūnai | |
| LT3628731T (lt) | Naujas antipresepsino antikūnas | |
| ITUB20155097A1 (it) | Anticorpi umanizzati anti-BAG3 | |
| BR112017002234A2 (pt) | anticorpos anti-pd-l1 |